The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

At the same time, the average R&D cost to move an asset from discovery to launch was an average $2.284B in 2023, the same amount as is 2022. Meanwhile, the group's average forecast peak sales per ...

This R&D cost represented about 25 percent of VMware’s total $3.09 billion in revenue. Comparatively, Broadcom spent $1.26 billion on R&D to achieve its $8.103 billion in total sales for its ...

The increasing costs and complexity of R&D in the pharmaceutical industry have necessitated the adoption of strategic ...

Furthermore, R&D costs have been rising ∼8% annually for the past several years, and prices are under substantial pressure globally. It could be argued that companies should shift much of their ...

Projected return on investment in pharma research and development (R&D) in 2024 has risen to 5.9%, continuing the upward ...

Immutep ( (IMMP)) has released its Q2 earnings. Here is a breakdown of the information Immutep presented to its investors.

However, critics argue that drug pricing strategies lack transparency, with many companies raising prices on existing medications without any corresponding increase in R&D costs. In early 2025 ...

Novo Nordisk may be reorganizing its early-stage R&D capabilities, but the Danish pharma’s chief scientific officer has insisted that the changes aren’t primarily about laying off staff. | Novo ...